FCM
Farallon Capital Management’s Ascendis Pharma ASND Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $242K | Hold |
1,400
| – | – | ﹤0.01% | 109 |
|
|
2025
Q1 | $218K | Buy |
+1,400
| New | +$218K | ﹤0.01% | 112 |
|
|
2024
Q4 | – | Sell |
-1,400
| Closed | -$209K | – | 148 |
|
|
2024
Q3 | $209K | Buy |
+1,400
| New | +$209K | ﹤0.01% | 135 |
|
|
2024
Q2 | – | Sell |
-109,000
| Closed | -$16.5M | – | 165 |
|
|
2024
Q1 | $16.5M | Buy |
+109,000
| New | +$16.5M | 0.07% | 77 |
|
|
2021
Q3 | – | Sell |
-375,000
| Closed | -$49.3M | – | 300 |
|
|
2021
Q2 | $49.3M | Sell |
375,000
-625,000
| -63% | -$82.2M | 0.2% | 71 |
|
|
2021
Q1 | $129M | Hold |
1,000,000
| – | – | 0.64% | 41 |
|
|
2020
Q4 | $167M | Sell |
1,000,000
-250,000
| -20% | -$41.7M | 1% | 38 |
|
|
2020
Q3 | $193M | Buy |
1,250,000
+110,000
| +10% | +$17M | 1.33% | 28 |
|
|
2020
Q2 | $169M | Sell |
1,140,000
-236,349
| -17% | -$35M | 1.35% | 30 |
|
|
2020
Q1 | $155M | Buy |
1,376,349
+97,349
| +8% | +$11M | 1.33% | 27 |
|
|
2019
Q4 | $178M | Sell |
1,279,000
-271,000
| -17% | -$37.7M | 1.2% | 25 |
|
|
2019
Q3 | $149M | Buy |
1,550,000
+10,000
| +0.6% | +$963K | 1.13% | 26 |
|
|
2019
Q2 | $177M | Buy |
1,540,000
+40,000
| +3% | +$4.61M | 1.15% | 22 |
|
|
2019
Q1 | $177M | Buy |
1,500,000
+703
| +0% | +$82.7K | 1.33% | 22 |
|
|
2018
Q4 | $93.9M | Buy |
1,499,297
+42,000
| +3% | +$2.63M | 0.69% | 32 |
|
|
2018
Q3 | $103M | Hold |
1,457,297
| – | – | 0.61% | 33 |
|
|
2018
Q2 | $96.9M | Buy |
1,457,297
+170,497
| +13% | +$11.3M | 0.6% | 37 |
|
|
2018
Q1 | $84.2M | Buy |
+1,286,800
| New | +$84.2M | 0.58% | 35 |
|